In Vivo Characterization of the Mitochondrial Selective KATPOpener (3R)-trans-4-((4-Chlorophenyl)-N-(1H-imidazol-2-ylmethyl)dimethyl-2H-1-benzopyran-6-carbonitril Monohydrochloride (BMS-191095): Cardioprotective, Hemodynamic, and Electrophysiological Effects

Autor:	Raymond B. Darbenzio, Gary J. Grover, Albert J. D'Alonzo, Thomas A. Hess, Charles S. Parham, Mohinder S. Bathala
Rok vydání:	2002
Předmět:	Pharmacology Cardioprotection business.industry Ischemia Stimulation medicine.disease Potassium channel In vitro Benzopyran chemistry.chemical_compound chemistry In vivo Cardiac conduction medicine Molecular Medicine business
Zdroj:	Journal of Pharmacology and Experimental Therapeutics. 303:132-140
ISSN:	1521-0103 0022-3565
DOI:	10.1124/jpet.102.036988
Popis:	Recent studies have shown the importance of mitochondrial ATP-sensitive potassium channels (K ATP ) in cardioprotection, and studies in vitro have shown that the benzopyran analog (3 R )- trans - 4-((4-chlorophenyl)- N -(1 H -imidazol-2-ylmethyl)dimethyl-2 H -1-benzopyran-6-carbonitril monohydrochloride (BMS-191095) is a selective mitochondrial K ATP opener with cardioprotective activity. The goal of this study was to show selective cardioprotection for BMS-191095 in vivo without hemodynamic or cardiac electrophysiological effects expected for nonselective K ATP openers. BMS-191095 reduced infarct size in anesthetized dogs (90-min ischemia + 5-h reperfusion) in a dose-dependent manner (ED 25 = 0.4 mg/kg i.v.) with efficacious plasma concentrations of 0.3 to 1.0 μM, which were consistent with potency in vitro. None of the doses of BMS-191095 tested caused any effect on peripheral or coronary hemodynamic status. Further studies in dogs showed no effects of BMS-191095 on cardiac conduction or action potential configuration within the cardioprotective dose range. In a programmed electrical stimulation model, BMS-191095 showed no proarrhythmic effects, which is consistent with its lack of effects on cardiac electrophysiological status. BMS-191095 is a potent and efficacious cardioprotectant that is devoid of hemodynamic and cardiac electrophysiological side effects of first generation K ATP openers, which open both sarcolemmal and mitochondrial K ATP . Selective opening or activation of mitochondrial K ATP seems to be a potentially effective strategy for developing well tolerated and efficacious K ATP openers.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::6c666ad0e7d55c0a2bed6ea6578530b7 https://doi.org/10.1124/jpet.102.036988 Zobrazit plný text záznamu